Bio-Cancer Treatment International Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 7

Bio-Cancer Treatment International General Information

Description

Developer of human malignancies and auto-immune disorders treatment intend to safe and effective treatments of multiple cancer indications and auto-immune disorders. The company's patented drugs are arginine depleting agents that retard tumor growth, enabling patients to get treated and cured in an effective and easy way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 302, 3/F Building 20E, 20 Science Park East Avenue
  • Hong Kong Science Park, New Territories, Shatin District
  • Hong Kong
  • Hong Kong
+852 2521
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • Room 302, 3/F Building 20E, 20 Science Park East Avenue
  • Hong Kong Science Park, New Territories, Shatin District
  • Hong Kong
  • Hong Kong
+852 2521

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bio-Cancer Treatment International Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 01-Sep-2016 Completed Clinical Trials - Phase 2
6. Grant 01-Jan-2014 Completed Clinical Trials - Phase 2
5. Grant 01-Jan-2010 Completed Clinical Trials - Phase 1
4. Later Stage VC 01-Jan-2006 Completed Pre-Clinical Trials
3. Grant 01-Jan-2004 Completed Startup
2. Grant 01-Jan-2002 Completed Startup
1. Grant 01-Jan-2001 Completed Startup
To view Bio-Cancer Treatment International’s complete valuation and funding history, request access »

Bio-Cancer Treatment International Patents

Bio-Cancer Treatment International Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021256801-A1 Methods of treating viral infections using arginase Inactive 17-Apr-2020
CA-3180529-A1 Methods of treating viral infections using arginase Pending 17-Apr-2020
EP-4135754-A1 Methods of treating viral infections using arginase Inactive 17-Apr-2020
EP-4135754-A4 Methods of treating viral infections using arginase Inactive 17-Apr-2020
US-20230149521-A1 Methods of treating viral infections using arginase Inactive 17-Apr-2020 A61K38/50
To view Bio-Cancer Treatment International’s complete patent history, request access »

Bio-Cancer Treatment International Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
HKSTP Ventures Corporate Venture Capital Minority
Hong Kong Science & Technology Parks Accelerator/Incubator Minority
Pivotal Life Sciences Asset Manager Minority
Government of China Government
Shanghai Municipal Government Government
You’re viewing 5 of 7 investors. Get the full list »

Bio-Cancer Treatment International FAQs

  • When was Bio-Cancer Treatment International founded?

    Bio-Cancer Treatment International was founded in 2000.

  • Where is Bio-Cancer Treatment International headquartered?

    Bio-Cancer Treatment International is headquartered in Hong Kong, Hong Kong.

  • What industry is Bio-Cancer Treatment International in?

    Bio-Cancer Treatment International’s primary industry is Drug Discovery.

  • Is Bio-Cancer Treatment International a private or public company?

    Bio-Cancer Treatment International is a Private company.

  • What is Bio-Cancer Treatment International’s current revenue?

    The current revenue for Bio-Cancer Treatment International is .

  • Who are Bio-Cancer Treatment International’s investors?

    HKSTP Ventures, Hong Kong Science & Technology Parks, Pivotal Life Sciences, Government of China, and Shanghai Municipal Government are 5 of 7 investors who have invested in Bio-Cancer Treatment International.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process